Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.

Dos Santos Fernandes GF, de Souza PC, Moreno-Viguri E, Santivañez-Veliz M, Paucar R, Pérez-Silanes S, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Man Chin C, da Silva PB, Chorilli M, Solcia MC, Ribeiro CM, Silva CSP, Marino LB, Bosquesi PL, Hunt DM, de Carvalho LPS, de Souza Costa CA, Cho SH, Wang Y, Franzblau SG, Pavan FR, Dos Santos JL.

J Med Chem. 2017 Oct 26;60(20):8647-8660. doi: 10.1021/acs.jmedchem.7b01332. Epub 2017 Oct 16.

2.

Synthesis and Preliminary Evaluation of N-Oxide Derivatives for the Prevention of Atherothrombotic Events.

Rosseto LA, Pires ME, Melchior AC, Bosquesi PL, Pavan AR, Marcondes S, Chung MC, Santos JL.

Molecules. 2015 Oct 7;20(10):18185-200. doi: 10.3390/molecules201018185.

3.

Pharmacological evaluation and preparation of nonsteroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit.

de Melo TR, Chelucci RC, Pires ME, Dutra LA, Barbieri KP, Bosquesi PL, Trossini GH, Chung MC, dos Santos JL.

Int J Mol Sci. 2014 Apr 4;15(4):5821-37. doi: 10.3390/ijms15045821.

4.

Antiplatelet and antithrombotic activities of non-steroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit.

Chelucci RC, Dutra LA, Lopes Pires ME, de Melo TR, Bosquesi PL, Chung MC, Dos Santos JL.

Molecules. 2014 Feb 17;19(2):2089-99. doi: 10.3390/molecules19022089.

5.

Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.

Blau L, Menegon RF, Trossini GH, Molino JV, Vital DG, Cicarelli RM, Passerini GD, Bosquesi PL, Chin CM.

Eur J Med Chem. 2013 Sep;67:142-51. doi: 10.1016/j.ejmech.2013.04.022. Epub 2013 May 20.

PMID:
23851115
6.

Pharmacological evaluation and preliminary pharmacokinetics studies of a new diclofenac prodrug without gastric ulceration effect.

Santos JL, Moreira V, Campos ML, Chelucci RC, Barbieri KP, de Castro Souto PC, Matsubara MH, Teixeira C, Bosquesi PL, Peccinini RG, Chin CM.

Int J Mol Sci. 2012 Nov 19;13(11):15305-20. doi: 10.3390/ijms131115305.

7.

Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives.

Dos Santos JL, Lanaro C, Chelucci RC, Gambero S, Bosquesi PL, Reis JS, Lima LM, Cerecetto H, González M, Costa FF, Chung MC.

J Med Chem. 2012 Sep 13;55(17):7583-92. doi: 10.1021/jm300602n. Epub 2012 Aug 21.

PMID:
22889416
8.

Advances in drug design based on the amino Acid approach: taurine analogues for the treatment of CNS diseases.

Chung MC, Malatesta P, Bosquesi PL, Yamasaki PR, Santos JL, Vizioli EO.

Pharmaceuticals (Basel). 2012 Oct 23;5(10):1128-46. doi: 10.3390/ph5101128.

9.

A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds.

Chung MC, Bosquesi PL, dos Santos JL.

Curr Pharm Des. 2011;17(32):3515-26. Review.

PMID:
22074424
10.

Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach.

Bosquesi PL, Melo TR, Vizioli EO, Santos JL, Chung MC.

Pharmaceuticals (Basel). 2011 Oct 27;4(11):1450-1474. Review.

11.

Assessment of the in vivo genotoxicity of new lead compounds to treat sickle cell disease.

Dos Santos JL, Longhin Bosquesi P, Varanda EA, Moreira Lima L, Chung MC.

Molecules. 2011 Apr 6;16(4):2982-9. doi: 10.3390/molecules16042982.

12.

Prodrugs for the treatment of neglected diseases.

Chung MC, Ferreira EI, Santos JL, Giarolla J, Rando DG, Almeida AE, Bosquesi PL, Menegon RF, Blau L.

Molecules. 2007 Mar 19;13(3):616-77. Review.

Supplemental Content

Loading ...
Support Center